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Background: Widespread prevalence of extended-spectrum βeta-lactamase
producing Escherichia coli (ESBL-producing E. coli) limits the infection therapeutic
options and is a growing global health problem. In this study our aim was to investigate
the antimicrobial resistance profile of the E. coli in hospitalized and out-patients in
Cyprus.
Results: During the period 2010–2014, 389 strains of E. coli were isolated from urine
samples of hospitalized and out-patients in Cyprus. ESBL-producing E. coli, was
observed in 53% of hospitalized and 44% in out-patients, latest one being in 2014.
All ESBL-producing E. coli remained susceptible to amikacin, carbapenems except
ertapenem (in-patients = 6%, out-patients = 11%).
Conclusion: High emerging ESBL-producing E. coli from urine samples in hospitalized
and out-patients is an extremely worrisome sign of development of untreatable
infections in the near future on the island. We therefore emphasize the immediate
need for establishment of optimal therapy guidelines based on the country specific
surveillance programs. The need for new treatment strategies, urgent prescription
habit changes and ban of over-the-counter sale of antimicrobials at each segment of
healthcare services is also discussed in this research.
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INTRODUCTION
Urinary tract infections (UTIs) called cystitis is one of the most common bacterial infection in
humans and Escherichia coli (E. coli) causes the vast majority of UTIs worldwide (Picozzi et al.,
2014). Furthermore, UTI-causing bacteria is becoming more resistant to available antimicrobials
with the increased incidence of Extended-Spectrum Beta-Lactamase (ESBL) since its ﬁrst detection
in1980s in Germany, shortly after the use of the oxyimino β-lactam drugs (Rice et al., 1990;
Livermore and Hawkey, 2005). The ESBL strains are associated with resistance to amino and
ureidopenicillins, oxyiminocephalosporins and monobactams, which are the most commonly used
drugs in the treatment of various bacterial infections (Bradford, 2001; Kim et al., 2002; Kotra
et al., 2002). ESBL genes are generally transmissible and they can be acquired between bacteria by
horizontal gene transfer mechanism, mainly using conjugation. The most common genetic variant
of ESBL is CTX-M (Paterson and Bonomo, 2005).
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The ESBL-producing E. coli is isolated from cystitis both
in hospitalized and out-patients and is increasingly posing
signiﬁcant therapeutic challenges (Hyle et al., 2005). It
is causing greater use of other expensive antimicrobials
(such as carbapenems), prolonged hospital stay, increasing
morbidity, mortality and health care costs (Mehrgan and Rahbar,
2008).
Antimicrobial resistance and its spread is increasing due to
misuse or overuse of antimicrobials, while the discovery of
the potential novel antimicrobials has slowed drastically in last
decade (Cantas et al., 2013). Most of the developed countries
have recognized the importance of the acquired antimicrobial
resistance surveillance programs to track the changes in the
antimicrobial susceptibility of certain public health threatening
pathogens to devise appropriate strategies for their control
(NORM/NORM-VET, 2013; ECDC, 2014). In particular, the
incidence of ESBL-producing organisms is diﬃcult to resolve
at the wider geographic scale level, mostly due to diﬃculty in
detecting ESBLs and inconsistencies in reporting (Steward et al.,
2000). Recently, an obvious increase in the prevalence of multi
drug resistant (MDR) and ESBL-producing E. coli isolates from
human sources has been observed throughout the globe (Gupta,
2007; Cantón et al., 2008; Fatemeh et al., 2012; Lu et al., 2012;
Allocati et al., 2013; Picozzi et al., 2013). From a European
aspect; the highest prevalence was in Bulgaria, Slovakia, and
Italy (22–36%); whereas the lowest occurrence of the MDR
E. coli were found to be in Sweden, Norway, and Finland (3–
5%). Recently, the ESBL-producing E. coli prevalence was found
to be about 15% in Eastern Europe including Turkey with
the highest percentage resistance (25.2%; Balode et al., 2013).
On the other hand; southern Cyprus had the highest third
generation cephalosporin resistant E. coli occurrence (38.9%)
in 2014; meanwhile it was found to be lowest in Scandinavian
countries (i.e., Sweden with 3%; ECDC, 2014). The broad extent
of the ESBL-producing Enterobacteriaceae distribution in the
parts of Africa, Asia and the Indian subcontinent have lately
begun to be understood with the increasing number reports.
The occurrence of the ESBL-producing E. coli increased in
diﬀerent parts of China (13–35%; Hawkey, 2008) and Africa (35–
65%; Ruth et al., 2011). Besides, incredibly high emerge of the
ESBLs prevalence up to 80% in India is worrying (Nasa et al.,
2012).
The frequent identiﬁcation of ESBL-producing E. coli from
urine samples prompted our interest to investigate the resistance
proﬁle of E. coli in hospitalized and out-patients with cystitis
in Cyprus. To our knowledge, there are no known previous
studies on these issues on the island. The interventions
needed to meet the challenge are discussed in this study, as
well.
MATERIALS AND METHODS
During the period 2010–2014, 389 strains of E. coli were isolated
from urine samples of hospitalized and out-patients in Cyprus
(Table 1). Urine samples (50 mL) were collected in universal
container. The samples inoculated using an inoculating loop of
10 μL volume calibration on blood agar and EMB mediums that
incubated overnight at 37◦C in the Microbiology Laboratory of
the Near East University Hospital (Nicosia, Cyprus). Samples
were further examined with the BD Phoenix 100 Automated
Microbiology System (Becton Dickson, USA) and Oxoid
combination disk test methods. The inoculated PhoenixTM
panels were placed into the PhoenixTM instrument for incubation
and continuous reading. The following antimicrobial agents were
used in the PhoenixTM ESBL test: Ceftazidime, Ceftriaxone, and
Ceftazidime. The ESBL result was determined based on all the
responses within 5–11 h.
Antimicrobial sensitivity records for each isolate yearly were
coded in aMicrosoft Excel 2013 R© spreadsheet and the percentage
(%) antimicrobial resistance displayed as a histogram (Cantas
et al., 2011). Changes in resistance prevalence over time within
in-patients and out-patients were assessed by chi-square tests.
RESULTS AND DISCUSSION
The prevalence of ESBL-producing E. coli was found to be
relatively higher in hospitalized patients than out-patients during
the last four years in urine culture isolates. The UTIs rate caused
by ESBL-producing E. coli among hospitalized patients increased
from 36% in 2010–2011 to 53% in 2014 with a signiﬁcant rise
of up to 71% in 2013 (p < 0.001). However, a gradual upward
trend of ESBL-producing E. coli frequencies were also observed
from 2010–2011 (14%) to 2014 (44%; p < 0.001) in UTIs of
out-patients (Figure 1).
Frequent isolation of ESBL-producing of E. coli typically
took place in hospital settings (Rodríguez-Baño et al., 2004;
Livermore, 2007). Hospitalization, recurrent UTIs, catheter
applications (bioﬁlm formations) and previous antimicrobial
treatment (especially with third-generation cephalosporins) or
previous international travel were previously described as great
risk factors for the acquisition of these organisms (Rodríguez-
Baño et al., 2004; Woodford et al., 2004; Laupland et al., 2008;
Topaloglu et al., 2010; Kang et al., 2012). Inevitably, these
microbes today have begun to disseminate into the community
worldwide (Colodner et al., 2004; Rodríguez-Baño et al., 2004).
We have witnessed a recent 2.5-fold increase in the community-
onset UTIs due to ESBL-producing E. coli in our region since the
years 2010–2011 (Figure 1). These results are in line with recent
reports (Coque et al., 2008; Topaloglu et al., 2010; Doi et al., 2013;
Ansari et al., 2015) which highlight the rapid spread of these
TABLE 1 | The number of Escherichia coli isolates each year, cultured from
urine samples of hospitalized and out-patients.
Study population
Year In-patient Out-patient
2010/2011 29 46
2012 36 55
2013 40 66
2014 45 72
Sum 150 239
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FIGURE 1 | Percentage distribution of ESBL-producing Escherichia
coli in urine samples of hospitalized patients and out-patients
(2010/2011–2014).
strains in the community. However, the proportion of ESBL-
producing E. coli from out-patients with cystitis were found to
be only 2.1% in Norway, a country with the lowest levels of
antimicrobial consumption rates among the European countries
(ESAC, 2009; NORM/NORM-VET, 2013).
The high resistance rate among out-patients in this study
seems to be the result of widespread antimicrobial usage in
Cyprus without prescription requirements especially in the
northern part of the island. The actual deﬁned daily doses
(DDDs) of antimicrobials were not known per se during
this study. However, earlier sale trends of systemic anti-
infective agents in Cyprus revealed that there was one of the
highest values in comparison with other European countries
(Hadjimichael et al., 2006; ESAC, 2009). Another independent
cross-sectional study showed that 97,6% of community
pharmacists in the north of Cyprus engaged in inappropriate
antimicrobial dispensing without medical prescriptions (Kaya
Suer et al., 2015, unpublished survey). Furthermore, 60% of
the physicians adhered to international antibiotic prescribing
guidelines (Cantas, 2014, unpublished survey) that may not be
implemented in parallel with nation speciﬁc epidemiological
data in Cyprus. As resistance is becoming more widespread,
prudent use of antimicrobials has to be supervised. Prescribers
should prioritize diagnostics in order to make more targeted
antimicrobial treatment decisions.
Many of the ESBL-producing E. coli isolates were
found to be resistant to quinolones (ciproﬂoxacin and
norﬂoxacin; in-patients = 78%, out-patients = 79%),
gentamicin (in-patients = 45%, out-patients = 61%) and
trimethoprim/sulfamethoxazole (in-patients = 60%, out-
patients = 62%). On the contrary, all ESBL-producing E. coli
remained susceptible to amikacin, carbapenems (imipenem
and meropenem) except ertapenem (in-patients = 6%,
out-patients = 11%). Partial resistance to nitrofurantoin
(in-patients = 14%, out-patients = 11%) was also observed
(Figures 2 and 3).
Non-resistance to meropenem and imipenem might be due
to the limited usage of these antibiotics in northern Cyprus.
Nitrofurantoin is one of the oldest urinary anti-infective drugs
that have been widely used on the island. It has multiple action
mechanisms on bacteria and demand several mutations in order
to develop antimicrobial resistance that might explain its low
prevalence in this region.
All other non-ESBL-producing E. coli were sensitive to
imipenem, meropenem, amikacin, and mostly to nitrofurantoin
(in-patient = 91%, out-patient = 93%). The highest resistance
rates were against trimethoprim-sulfamethoxazole (in-
patient= 69%, out-patient: 41%) in the years 2010–2011 to 2014.
Antimicrobial resistance to cephalosporins (>50%, except
cefoxitin) in northern Cyprus was found to be signiﬁcantly
higher than in the Scandinavian countries (Sweden, Norway,
and Finland; 3–5.1%) which have more restricted antimicrobial
consumptions compared to other eastern European countries
such as Bulgaria (22.9%) and Slovakia (31%) (Allocati et al.,
2013). Cephalosporins have been frequently used for the
empirical treatment of UTIs which shows a clear evidence of a
strong relationship between prescribing habits and antimicrobial
resistance (Lindbäck et al., 2010; Allocati et al., 2013).
Reduced susceptibility to both ciproﬂoxacin (53%)
and gentamicin (26%) leaves clinicians only the choice of
carbapenem in such serious cystitis treatment on the island. The
ﬂuoroquinolone resistance range was found to be signiﬁcantly
lower in Sweden (8%) and Norway (9%) (European Centre for
Disease Prevention and Control [ECDPC], 2012), whereas it
was found to be 42% in northern Cyprus. Furthermore, the
prevalence of isolates resistant to aminoglycosides (amikacin and
gentamicin) was found to be around 2% in this study whereas
it was 4% in Sweden, 17% in Romania, Slovakia and Greece.
However, the prevalence of multi-resistant (≥3 drugs) non-ESBL
E. coli isolates were 24% in northern Cyprus, which recently were
discovered to range from approximately 1% in Sweden to 10% in
Romania and Slovakia.
The rise of ESBL-producing E. coli may lead to an increased
consumption of carbapenems especially ertapenem due to
the fact that it is administered only once daily, unlike the
other carbapenems (Prakash et al., 2009). On the other, it
facilitates the emergence and spread of carbapenemases. This
is a great threat for public health and compels exploration
of alternative therapeutic options. Herein, Cefoxitin has been
recently suggested by (Raphaël et al., 2012; Guet-Revillet et al.,
2014) as an alternative to carbapenems for the treatment of
UTIs caused by ESBL-producing E. coli. Over 90% of the ESBL-
producing E. coli isolates from hospitalized and out-patients were
found to be sensitive to cefoxitin for the last 2 years (2013–
2014) that might be recommended for the therapy of complicated
cystitis rather than carbapenems as the ﬁrst choice in northern
Cyprus (Figures 2 and 3).
There is a limited number of practical solutions for
the treatment of multi-resistant gram-negative bacteria.
Non-antimicrobial prescription is recommended to suppress
bacteriuria in the elderly without clinical signs of UTI (Raphaël
et al., 2012; Guet-Revillet et al., 2014).
Extended courses of antimicrobials due to complicated cystitis
should only be used in speciﬁc situations such as for men with a
relapsing infection in prostate (Williams and Schaeﬀer, 2004).
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FIGURE 2 | Antibiotics susceptibility testing for all E. coli strains isolated from in-patients with cystitis (2010/2011–2014).
FIGURE 3 | Antibiotics susceptibility testing for all E. coli strains isolated from out-patients with cystitis(2010/2011–2014).
The oral options available for the treatment of complicated
UTIs caused by ESBL-producing E. coli with concurrent
resistance to trimethoprim and quinolones are limited. In case of
susceptibility, nitrofurantoin treatment can be recommended for
lower UTIs but resistance may develop upon treatment (Pallett
and Hand, 2010; Cantas, 2014, unpublished survey). Rather,
some immune-modulating cranberry, pre-probiotic products
are recommended to reduce the frequency of recurrent UTIs
(Williams and Schaeﬀer, 2004; Wagenlehner et al., 2005;
McMurdo et al., 2009).
It is known that a combination of antimicrobials particularly
cephalosporin with clavulanic acid has been used to treat
UTIs caused by CTX-M ESBL-producing E. coli in clinical
practice (Livermore et al., 2008), which are unlicensed in
northern Cyprus. Empirical treatment with cephalosporins
enhanced by clavulanic acid is not recommended by the authors.
The induction of AmpC enzymes in Enterobacteriaceae may
inactivate the cephalosporin in bacteria. UTIs may get even more
severe and course with bacteraemia. Herein, delay in adequate
therapy will lead to adverse outcomes and potentially increased
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mortality and morbidity (Kumar et al., 2006). Intravenous
antimicrobial therapy (chosen according to the susceptibility
pattern of the organism) should be administered. Unfortunately,
our ESBL-producing E. coli isolates were not tested in term
of resistance against fosfomycin, which represents a current
favorite choice among practitioners due to limited side eﬀects
and simplicity for the treatment of MDR E. coli causing UTIs in
literature (Estebanez et al., 2009; Cho et al., 2015). The immediate
inclusion of fosfomycin antimicrobial resistance test is needed in
Cyprus.
Besides strategies for smarter antimicrobial use, several new
treatment choices can be potentially administered in Cyprus,
such as phage therapy, antimicrobial peptide (AMPs) therapy and
immunotherapy (Haq et al., 2012; Worthington and Melander,
2013). Especially, the eﬀective use of therapeutic bacteriophages
was already started over a century ago that has been later
on underestimated by the discovery of the antimicrobials
(Kutateladze and Adamia, 2010; Haq et al., 2012; Keen, 2012).
Mainly, Eastern European and Russianmedical doctors have used
the phage therapy to treat insisting MDR bacterial infections
(Kutateladze and Adamia, 2010; Abedon et al., 2011). Highly
speciﬁc and bacteria lysing eﬀective phages for diﬀerent E. coli
strains have been previously published (Brüssow, 2005; Maura
et al., 2012; Sillankorva et al., 2012; Tsonos et al., 2012).
Furthermore, sequence-speciﬁc gene fragments that can be
injected into the harmful pathogens by individually designed
phages have also been lately described (Lu and Koeris, 2011;
Bikard et al., 2014; Qadir, 2015). This technology creates
opportunities to kill the targeted pathogens in complex bacterial
populations while preventing the spread of plasmid- borne
resistance genes, in endemic countries, such as Cyprus.
The majority of the E. coli strains causing UTIs can produce
bioﬁlms, which signiﬁcantly increase resistance to antimicrobials
and natural immune- system, whereas phages are able to pass
through the extracellular matrix, to degrade the bioﬁlm and kill
the bacteria (Doolittle et al., 1995; Lacroix-Gueu et al., 2005).
There are also accumulating reports in the literature regarding
activity of AMPs that contribute to innate immune responses and
destroy the harmful pathogens such as E. coli (Corrales-Garcia
et al., 2013; Lira et al., 2013). Those small peptides enter into
membrane bilayer of the microbes and form channels resulting
in cell death (Hassan et al., 2012).
In case of insisting UTIs every other aspect of diagnostic
investigations (i.e., CT, Magnetic Resonance Imagining, pelvic
and renal ultrasound) should be carried out to ﬁnd out
the complicating factors rather than simple addition of
antimicrobials.
The scope of this study was limited with investigation of
phenotypical ESBL-producing E. coli prevalence in Cyprus.
Although, continuous epidemiologic data collection supported
by molecular typing are needed on the entire island in future.
According to recent metagenomic studies, the environment is
the largest gene pool which is closely related to those conferring
resistance in human pathogens (Cantas et al., 2013; Cantas
and Suer, 2014). It is therefore not possible to eradicate any
multi-resistant genes posing bugs on the earth. Yet routine
antimicrobial resistance screenings from gut microbes isolated
from environment and animals can at least contribute to a better
understanding and control of possible spread of ‘super bugs’
and resistance genetic elements on the island. Each year, over
two million tourists visit Cyprus. Hypothetically, new resistance
genes may travel in and out of the country with potential
pandemics.
CONCLUSION
This study withholds the ﬁrst nationwide antimicrobial resistance
test records of previously isolated microbes from urine samples
in Cyprus. The high frequency of ESBL-producing E. coli
causing cystitis is an emerging problem in hospitalized and out-
patients on the island. Non-resistance to amikacin, meropenem,
imipenem and relatively high susceptibility to nitrofurantoin can
be considered as good choices for the empirical treatment of
complicated UTIs in Cyprus.
Continuous surveillance of bacterial resistance is needed to
generate essential epidemiological data which promotes and
directs country speciﬁc stewardship activities. Diagnostic tests
should be more commonly used in routine clinical practice for
targeted therapy. Ideally, patients should have access to precise
information on the infectious disease, antimicrobial resistance
and its consequences instead of simple and easy access to drugs
without prescriptions. An immediate ban of over-the-counter
sale of antimicrobials has to be implemented at each segment of
healthcare. As a result, it can be argued that further work and
new strategies for continuous dissemination of multidisciplinary
research ﬁndings related to antimicrobial resistance development
on the island is needed.
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